Trypanothione
Also known as: N1,N8-bis(glutathionyl)spermidine, T(SH)2, Trypanothione disulfide (TS2), TSH2
Source Trypanothione at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Trypanothione (N1,N8-bis(glutathionyl)spermidine) is a dithiol molecule unique to trypanosomatid parasites such as Trypanosoma and Leishmania. It acts as the primary intracellular redox buffer, supplying electrons to parasite‑specific peroxidases and other antioxidant enzymes, thereby protecting the organism from oxidative damage.
Mechanism of Action
In trypanosomatids, reduced trypanothione donates electrons to three major peroxidase families—2‑Cys‑peroxiredoxins, non‑selenium glutathione peroxidases, and ascorbate peroxidases—through redox shuttles like tryparedoxin, ascorbate, or glutathione. The oxidized form (disulfide) is regenerated to the reduced state by trypanothione reductase, which uses NADPH as a cofactor. This cycle maintains the parasite’s thiol‑disulfide balance and is absent in mammalian cells, which rely on the glutathione system.
What the Research Shows
Multiple reviews emphasize that trypanothione is indispensable for peroxide detoxification and overall viability of trypanosomatids. Genetic and biochemical studies show that loss of trypanothione‑dependent peroxidases or trypanothione reductase is lethal to the parasites. Recent work (2024, 2017) details structure‑based efforts to inhibit trypanothione reductase, synthetase, and related enzymes, highlighting several small‑molecule leads that impair parasite growth in vitro and in animal models. No clinical trials have been reported; the evidence remains at the pre‑clinical stage.
Reported Benefits
Targeting the tryptanothione pathway offers a parasite‑specific approach because the molecule and its enzymes are absent from humans. Inhibitors of trypanothione reductase and synthetase have demonstrated selective antiparasitic activity in laboratory studies, suggesting potential for new treatments against diseases such as Chagas disease, African sleeping sickness, and leishmaniasis.
Limitations of the Evidence
No tryanothione‑based therapeutics have received regulatory approval. Existing data are limited to biochemical assays, cell‑culture experiments, and animal infection models. The redundancy of peroxidase systems may reduce the impact of inhibiting a single enzyme, and the translation of in‑vitro potency to safe, effective human therapy remains uncertain.
Safety Considerations
Trypanothione itself is not used clinically, so direct safety data are unavailable. Experimental inhibitors described in the literature have not been evaluated in humans; potential off‑target effects on host thiol‑redox systems cannot be excluded. Caution is advised when extrapolating pre‑clinical toxicity findings.
How It Is Administered
Research‑grade compounds are typically applied in vitro to cultured parasites or administered to animal models via injection or oral gavage, depending on the study design. No approved formulation, dosage, or route for human use exists.
Routes of Administration
Goals & Uses
- Drug target identification for African sleeping sicknessAntiparasitic ResearchHigh
- Drug target identification for Chagas diseaseAntiparasitic ResearchHigh
- Neglected tropical disease drug discoveryDrug DiscoveryHigh
- Drug target identification for leishmaniasisAntiparasitic ResearchHigh
- Redox biochemistry researchBasic ScienceHigh
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
- Not applicable (research compound, not therapeutic)GeneralAbsolute
Regulatory Status
- European UnionUnapprovedNot an approved drug; research biochemical only
- United StatesUnapprovedNot an approved drug; research biochemical only
- United KingdomUnapprovedNot an approved drug; research biochemical only
Not approved as a therapeutic agent in any jurisdiction. Used exclusively as a research tool/biochemical standard and as a validated drug target scaffold.
Evidence & Sources
- Journal ArticleModerateCastro H, Tomás AM2008-01-01T00:00:00.000000Z
- Journal ArticleModerateKrauth-Siegel LR, Comini MA, Schlecker T2007-01-01T00:00:00.000000Z
- Journal ArticleModerateUrbina JA2002-01-01T00:00:00.000000Z
- Journal ArticleModerateLu J, Holmgren A2014-01-01T00:00:00.000000Z
- Journal ArticleModerateGonzález-Montero MC, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateIlari A, et al.2017-01-01T00:00:00.000000Z
Frequently Asked Questions
Why is trypanothione considered a drug target?
Because it is essential for parasite antioxidant defenses and is absent in mammals, inhibiting its synthesis or recycling can selectively cripple trypanosomatids without harming host cells.
Are there any drugs on the market that act on tryptanothione?
No. All agents that interfere with tryptanothione metabolism are still in the research phase; none have progressed to regulatory approval.
What kinds of experiments use tryptanothione?
Scientists use purified tryptanothione to study redox reactions in vitro, and they test enzyme inhibitors in cultured parasites or infected animal models to assess antiparasitic activity.
Could targeting tryptanothione affect human cells?
Human cells lack tryptanothione and rely on glutathione; however, inhibitors must be screened for cross‑reactivity with human thiol‑redox enzymes to avoid unintended toxicity.
What diseases could benefit from tryptanothione‑targeted therapies?
Potentially African trypanosomiasis, Chagas disease, and various forms of leishmaniasis, which are caused by trypanosomatid parasites that depend on the tryptanothione system.
What is Trypanothione?
Trypanothione (N1,N8-bis(glutathionyl)spermidine) is a dithiol molecule unique to trypanosomatid parasites such as Trypanosoma and Leishmania. It acts as the primary intracellular redox buffer, supplying electrons to parasite‑specific peroxidases and other antioxidant enzymes, thereby protecting the organism from oxidative damage.
What is Trypanothione used for?
Trypanothione is educationally associated with: Drug target identification for African sleeping sickness, Drug target identification for Chagas disease, Neglected tropical disease drug discovery, Drug target identification for leishmaniasis, Redox biochemistry research. Educational only — not medical advice.
How is Trypanothione administered?
Recorded routes of administration: Research Use Only.